HomeAI · summaries
Storia in 3 fonti
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking licensing deals in China, experts say. For the first time, a federal jury has found a drugmaker liable in a pay-for-delay case. And more.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
- ·
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for…
